What Researchers Did
This review article summarized recent research advancements in behavioral, developmental, and drug therapies for autism spectrum disorders (ASD) in children.
What They Found
The incidence of autism spectrum disorders (ASD) is increasing worldwide, and early individualized comprehensive intervention has been shown to significantly improve prognosis. While behavioral and developmental intervention remains the primary therapy, certain drugs can enhance the efficacy of behavioral interventions for concomitant symptoms, and emerging therapies like bumetanide, oxytocin, vitamin D, and hyperbaric oxygen therapy show promise for improving core ASD symptoms.
What This Means for Canadian Patients
Canadian patients with autism spectrum disorders (ASD) could benefit from early, individualized comprehensive interventions, which are shown to improve prognosis. While behavioral and developmental therapies remain central, ongoing research into new drug treatments offers hope for improved management of both core and concomitant symptoms.
Canadian Relevance
This review article does not have a direct Canadian connection.
Study Limitations
As a review article, this study synthesizes existing research without presenting new empirical data or conducting a meta-analysis.